Foreword of the editor

Editor-in-Chief: Gábor L. Kovács, MD, PhD, DSc

This themed issue of the eJIFCC on Publication Ethics is based on the lectures of the symposium “PEER REVIEW AND ETHICS IN PUBLICATION IN THE ELECTRONIC AGE” organized by the Communications and Publications Division of the IFCC. The symposium was presented at the IFCC Worldlab Congress in Istanbul in 2014. Organizers of the symposium and thus the guest-editors of this themed issue were Professor Khosrow Adeli (Canada) and Dr. Peter Vervaart (Australia).

Dr. Khosrow Adeli, Ph.D., FCACB, NACB, DABCC is currently a Senior Scientist in the Program in Molecular Structure and Function, Research Institute, The Hospital for Sick Children, University of Toronto. He is also the head and full professor of Clinical Biochemistry at the Hospital for Sick Children and the Departments of Biochemistry, and Laboratory Medicine & Pathobiology at the University of Toronto in Toronto, Canada. He is the Director of Point of Care Testing program at the Hospital for Sick Children in Toronto.

Dr. Adeli is a fellow of the Canadian Academy of Clinical Biochemistry and a diplomate of the American Board of Clinical Biochemistry. He is currently the Editor-in-Chief of the Critical Reviews in Clinical Laboratory Sciences. Dr. Adeli served as the Editor-in-Chief of the Clinical Biochemistry journal for 7 years (1999-2006).

He is an editorial board member of the Clinical Biochemist Reviews. He served (2006-2010) as the President of COMACC, the Commission on Accreditation in Clinical Chemistry, a North American organization responsible for accreditation of clinical chemistry training programs in the USA and Canada. He currently serves as the Chair of the Communications and Publications Division of the International Federation of Clinical Chemistry (IFCC).

Dr. Adeli has been actively involved in both basic and clinical laboratory research since 1988 and has published over 250 articles and abstracts in the field of lipid and lipoprotein metabolism, diabetic dyslipidemia, and metabolic disorders. He has received several national and international awards for research excellence including the 2014 Distinguished Service Award of the University of Toronto, the 2011 Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology (CSATVB) Scientific Excellence Award, the 2008 Merck Senior Investigator Award of the Canadian Lipoprotein Conference, the 2006 Canadian Society of Clinical Chemistry National Award for outstanding contributions to clinical chemistry, 2004 Canadian Academy of Clinical Biochemistry National Award, and the 1999 Canadian Society of Clinical Chemistry Research Excellence Award. He has also been active in clinical chemistry research and is the
principal investigator of the CALIPER (Canadian Laboratory Initiative on Pediatric Reference Interval Database) project aimed at the establishment of a laboratory reference interval database for biomarkers of pediatric disease.

Dr. Peter Vervaart, PhD, DipFLMgt, GradCert, PSM, FAACB, FFSc(RCPA) is Principal Scientist in Pathology Services at the Royal Hobart Hospital and has appointments with the University of New South Wales, where he convenes the Molecular Basis of Disease Modules of the Masters in Drug Development, and University of Tasmania. He has a PhD from the University of Melbourne and a Diploma in Frontline Management and Graduate Certificate in Public Sector Management from Swinburne and Flinders Universities respectively. He is a Fellow of the Australasian Association of Clinical Biochemists (AACB) of which he is also President and is a Foundation Fellow of the Faculty of Science of the Royal College of Pathologists of Australasia (RCPA). He is also Publications and Distance Learning Coordinator and Chair of the Internet and e-Learning Committee of the International Federation of Clinical Chemistry (IFCC).